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Abstract
Background: Therapeutic options in human mitochondrial oxidative phosphorylation (OXPHOS) diseases have been poorly
evaluated mostly because of the scarcity of cohorts and the inter-individual variability of disease progression. Thus, while a
high fat diet (HFD) is often recommended, data regarding efficacy are limited. Our objectives were 1) to determine our
ability to evaluate therapeutic options in the Harlequin OXPHOS complex I (CI)-deficient mice, in the context of a
mitochondrial disease with human hallmarks and 2) to assess the effects of a HFD.
Methods and Findings: Before launching long and expensive animal studies, we showed that palmitate afforded long-term
death-protection in 3 CI-mutant human fibroblasts cell lines. We next demonstrated that using the Harlequin mouse, it was
possible to draw solid conclusions on the efficacy of a 5-month-HFD on neurodegenerative symptoms. Moreover, we could
identify a group of highly responsive animals, echoing the high variability of the disease progression in Harlequin mice.
Conclusions: These results suggest that a reduced number of patients with identical genetic disease should be sufficient to
reach firm conclusions as far as the potential existence of responders and non responders is recognized. They also positively
prefigure HFD-trials in OXPHOS-deficient patients.
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Introduction
Mitochondria play a vital role by producing most of the cellular
ATP via oxidative phosphorylation (OXPHOS) [1]. OXPHOS is
responsible for transferring energy from macronutrients to ATP
through a sequence of coordinated reactions by which macronu-
trients are oxidized, oxygen is reduced to water, and ADP is
phosphorylated to ATP. OXPHOS is catalyzed by the respiratory
chain (RC) which comprises the proton-pumping respirasome
associating complexes I, III, and IV, and a number of
dehydrogenases including complex II and the ATP synthasome
[2].
Inherited mitochondrial dysfunction causes heterogeneous and
often multisystemic disorders (mt or OXPHOS diseases) that
preferentially affect tissues with high-energy demands such as
brain [3], muscle and heart, although any organ can be affected at
any age [4,5]. Among them, defects of the RC complex I (CI) are
the most frequent [6].
While major progress has been made in the identification of the
molecular bases at the origin of OXPHOS defects including CI
deficiencies [7], no treatment is currently available [8]. Supportive
care includes nutritional modulations (specifically fat-enriched
diet) [9]. However, this scheme is mostly based on theoretical
assumptions or circumstantial reports. Experimental data that
would support it are still lacking. Harlequin (Hq) mouse is a
faithful model for CI deficiency, mimicking the human disease by
the variability of the severity and the progression rate of symptoms
[10]. This was a strong incentive to evaluate diet effect in Hq mice
under realistic conditions for a mt disease to prefigure human
trials.
The Hq phenotype is due to a proviral insertion in the X-linked
gene encoding the mt protein Apoptosis Inducing Factor (AIF)
[11] causing an 80% decrease in the AIF protein. Hemizygous
males and homozygous females exhibit a phenotype of variable
(albeit comparable) severity [10] with growth retardation,
progressive cerebellar ataxia, early fur abnormalities, optic tract
dysfunction with pigmentary retinopathy, and increased risk of
heart failure [11,12]. We previously established that Hq mice are
partially CI-defective [13] with a tissue specific and variable
progressive pattern [10]. Accordingly, CI deficiency was shown to
be the cause of the Hq phenotype [13,14]. As it reproduces many
features of human mt diseases, and because of the progressiveness
of its phenotype with a symptom-free interval, the Hq model is an
appropriate tool for investigating treatments aimed at fighting
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28823OXPHOS diseases [15]. We have shown that weight loss, baldness
and cerebellar ataxia were correlated parameters whose time
course closely reflected disease progression [10]. Notably, the first
AIF mutations were reported in 2 related (first cousins) male
patients affected with a typical and severe mt encephalomyopathy
[16]. Very recently, two brothers with prenatal ventriculomegaly
and severe mt encephalomyopathy were reported with a mutation
in AIF [17]. These reports of human AIF mutations validate AIF
depletion as a cause of human mt OXPHOS disease.
Fatty acids (FA) are well-known ligands of the peroxisome
proliferator-activated receptors (PPARs) [18,19,20] which partic-
ipate in the control of mt biogenesis in a number of tissues
[21,22,23,24]. The theoretical rational to use FA in mt diseases is
therefore well established as well as their mechanisms of action on
mitochondria.
Taking advantage of an available faithful model for mt disease
and of a promising therapeutic option (strong rational and
circumstantial reports [25,26,27,28]), we decided to test high fat
diet (HFD) in a placebo-controlled trial on a population of mice.
However, before launching a long and expensive animal study, we
verified that FA had indeed a positive impact in CI- deficient
human fibroblasts.
Results
Palmitate protects human Complex I deficient fibroblasts
from death
A number of crucial features in cells including ATP synthesis,
calcium handling and ROS generation presumably depend on mt
CI function. Thus it was not surprising that under our
experimental growth conditions, most cells with severe CI
deficiency died upon glucose withdrawal from the culture
medium. Notably, supplementing the growth medium with the
saturated fatty acid palmitate (100 mM palmitate, 1 mM L-
carnitine, 0.5 mg/mL BSA) protected a number of CI-deficient
cells from death triggered by glucose withdrawal. This effect was
particularly spectacular in one NDUFS1 (del222/D252G) [29]
mutant cell line (patient 1) for which death occurred within
72 hours after glucose withdrawal with full protection afforded by
100 mM palmitate (Fig. 1A). These cells were still viable after 8
days of culture in the absence of glucose but in the presence of
palmitate. In two other CI-defective cell lines (harbouring
mutations in NDUFS1 [del,44, 2cM/M707V], patient 2 [29]
and NDUFS4 [IVS1nt –1, GRA], patient 3 [30]), death occurred
within 170 hours after glucose withdrawal again with full
protection by palmitate (Table 1). FA death-preventive effect
was not observed in cells cultured with L-carnitine alone or BSA
alone (Table 2) confirming that the protective effect was
exclusively attributable to palmitate itself. A similar protection
was obtained with pyruvate (Fig. 1A) but not with succinate
(Table 2). There was no significant effect on cell survival/
proliferation of glucose withdrawal, palmitate, succinate or
pyruvate supplementation in control cell lines (Tables 2 and 3).
Protection from death afforded by pyruvate in culture medium of
RC deficient cells may partly be due to the well-known peroxide-
scavenging activity of this ketoacid [31]. Accordingly, pyruvate
fully protected control cells from death resulting from the H2O2
produced by glucose oxidase added to the culture medium
(Fig. 1B). No such protection from H2O2 insult could be observed
when adding palmitate to the culture medium. Under all
conditions, a full protection was provided by adding catalase
(Fig. 1B).
In the NDUFS1 mutant fibroblasts that significantly responded
to palmitate (patient 1), the protection from death was associated
with increase in RC activities demonstrated by polarographic and
spectrophotometric assays (Fig. 2 and 3). Noticeably, the
palmitate-induced death protection of these CI-deficient fibro-
blasts could not be ascribed to an uncoupling effect, as the very
Figure 1. Protection from cell death triggered by either glucose withdrawal in patient 1 (P1) cells (A) or hydrogen peroxide addition
in control cells (B) afforded by palmitate or pyruvate. A: In Patient 1 (P1) cells, death occurred within 72 hours after glucose withdrawal, when
cells were cultured in the presence of glutamine (open circles). When cells were cultured in the presence of 100 mM palmitate (dark squares) or 2 mM
pyruvate (crosses), these were significantly protected from death. B: Control cells were counted 24 hours after the addition of 2 mM pyruvate (Pyr) or
100 mM palmitate (Palm) in standard DMEM 4.5 g/L glucose, 4 mM glutamine medium (none) with or without 0.001 mg/mL glucose oxidase or
glucose oxidase and 350 ng/mL catalase. Pyruvate but not palmitate protects against H2O2-induced cell death. Values are means 6 SEM from
triplicate experiments. **: p,0.01 (Student’s two-tailed t test). Experimental procedures as described under Materials and methods.
doi:10.1371/journal.pone.0028823.g001
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process in the absence of palmitate (respiratory control: 1.160.1).
If anything, palmitate in culture medium improved respiratory
control (1.360.1) possibly by increasing respiration rate.
The clear effect of palmitate on cultured CI-deficient cells was
an incentive to extend the investigations on the potential effect of
long-chain saturated fatty acids using the CI-deficient Harlequin
mouse. With this aim, we studied the effect of a nine fold saturated
fatty acids-enriched food (high fat diet; HFD) on the course of the
Hq disease focusing on parameters that we have previously found
to be relevant for Hq disease progression.
HFD-fed Hq animals exhibit a slower progression of the
neurodegenerative phenotype
At one month of age, wild type (WT) animals fed with the
control diet (CD) obtained on average a score of 126623 in the
rotarod test. This score remained essentially unchanged up to six
months of age (Fig. 4A; closed symbols). There was a tendency
towards lower scores in HFD-fed WT animals from 4 months of
age which became more obvious at 5 months (Fig. 4A; open
symbols), presumably due to HFD-induced obesity [32]. In
comparison, Hq animals fed with the CD who had a score of
139623 comparable to WT animals at 1 month of age, lost about
17 points/month between 1 and 6 months: 262 points between 1
and 4 months and 240 points between 4 and 6 months (Fig. 4B;
closed symbols). The rotarod scores were significantly improved by
the high fat diet. At 1 month of age, HFD-fed Hq animals had an
average score of 135626 similar to WT animals (Fig. 4;
comparison A and B) only losing 9 points/month on average:
224 points between 1 and 4 months and 221 points between 4
and 6 months (Fig. 4B; open symbols). By the age of 4 months,
rotarod scores of the HFD-fed Hq animals were significantly
higher than the scores of CD-fed Hq animals and these better
Table 1. Palmitate-induced death protection in two other CI-
deficient human fibroblasts.
% dead cells
Patients Culture medium 0 h 170 h
P2 (NDUFS1) Glutamine 15627 5 63.5
Glutamine+palmitate 2063.2 2562.7
P3 (NDUFS4) Glutamine 2061.2 7064
Glutamine+palmitate 17621 8 63
Values are means 6 SEM from triplicate experiments; h: time from glucose
withdrawal in hours.
doi:10.1371/journal.pone.0028823.t001
Table 2. Effect of bovine serum albumin (BSA), L-carnitine,
(BSA+L-carnitine+palmitate) and succinate on glucose
withdrawal-induced cell death in patient 1 (P1) and control
(Ctrl) cells.
% dead cells (P1/Ctrl)
Culture medium 0 h 72 h 150 h
Glutamine 1563/9614 0 61.7/12628 5 63/1562
Glutamine+BSA 1563/8614 5 62/12629 0 65/1663
Glutamine+L-C 1062/10615 0 64/12638 8 64/1862
Glutamine+BSA+L-C+palm 1963/12612 2 62/12622 2 63/2062
Glutamine+succinate 1563/10614 5 62/12628 9 65/1961
Values are means 6 SEM from triplicate experiments; h: time from glucose
withdrawal in hours; L-C: L-carnitine; palm: palmitate.
doi:10.1371/journal.pone.0028823.t002
Table 3. Absence of cell death in control (Ctrl) cells after
glucose withdrawal, palmitate or pyruvate supplementation.
% dead cells
Culture medium 0 h 48 h 100 h 142 h 166 h
Glutamine 1060.5 10.961.5 1561.5 17.3621 8 62.6
Glutamine+palmitate 11.860.7 13.761.2 15.361.9 14.663.4 16.560.5
Glutamine+pyruvate 12.860.8 15.363.8 13.463.4 1661.7 17.860.6
Values are means 6 SEM from triplicate experiments; h: time from glucose
withdrawal in hours.
doi:10.1371/journal.pone.0028823.t003
Figure 2. Respiration and mitochondrial substrate oxidations
in patient 1 (P1) and control cells grown in the absence or
presence of palmitate. Intact P1 cell respiration was 51% higher in
cells grown in the presence of palmitate (comparison traces a and b). A
subsequent addition of 0.004% digitonin made cells (approximately
2.10
6 cells) permeable to small molecules including respiratory
substrates, with the subsequent dilution of respiratory substrates and
progressive arrest of oxygen consumption. Adding 10 mM succinate
(Succ) and 0.4 mM ADP triggered a rapid oxygen uptake which was
70% higher for P1 cells grown with palmitate (b). A similar effect, albeit
less pronounced of growing cells in the presence of palmitate could be
observed using control cells (comparison traces c and d). Numbers
along the traces are nmol/min/mg protein. Values are means 6 SEM
from triplicate experiments. Experimental procedures as described
under Materials and methods.
doi:10.1371/journal.pone.0028823.g002
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analyzing rotarod scores individually, the relative loss in rotarod
scores between 1 and 6 months of age ranged from 298% to
223% of the initial value of the CD-fed Hq animals (Fig. 5A) and
from 271% to +5% of the initial value of the HFD-fed Hq mice
(Fig. 5B). Notably, 2/17 (11%) animals of the CD-fed Hq mice
population (Fig. 5A) displayed a slower progression of the disease
reflecting the variability of the disease progression previously
reported in the Hq mice. Interestingly, 6/21 (29%) of the HFD-fed
Hq mice showed a preserved (19% of the individuals) or slightly
reduced (#10% of the initial value, 10% of the individuals)
rotarod performance (Fig. 5B, dark grey triangle). This population
(29%) of mice protected from disease when measured by rotarod,
clearly indicates the presence of a subset of Hq individuals who
indubitably respond to HFD.
It has been previously shown [10] that rotarod scores of the Hq
mice were correlated to the animal weights i.e. the most severely
ataxic individuals (as approximated by the rotarod score) had the
lowest weight. We first verified that there was no weight difference
between the 2 groups of Hq animals and confirmed that the HFD-
fed Hq animals were resistant to HFD-induced obesity observed in
the WT animals (Fig. 6) [33]. We also confirmed that Hq animals
and the WT mice consumed similar amounts of food per day (at
the age of 3 months, the average daily food intake was 460.5 g/d
or 13.561.5 kcal/d either CD or HFD), indicating normal food
intake. In keeping with this, we indirectly confirmed correct
absorption of the HFD since 1) at 6 months of age, after 24 hours
of fasting, the blood level of b-hydroxybutyrate (the major ketone
body) was significantly higher in HFD-fed individuals (Hq and
WT) than in CD-fed animals attesting for increased fatty acid b-
oxidation and subsequent ketogenesis (Fig. 7) and 2) at 6 months of
age, after 24 hours of fasting, the cerebellum phospholipid profile
was significantly different in HFD-fed individuals (Hq and WT,
with various complex phospholipids being more abundant) than
CD-fed animals confirming absorption of fats into the central
nervous system (CNS) (Fig. 8).
We next analyzed the individual evolution of the rotarod score
reported to the initial (1 month) weight. No impact of the initial
weight on the rotarod scores in the Hq mice (CD- or HFD-fed
animals) could be observed, ruling out the possibility of a weight-
associated bias (not shown).
We then analyzed the scores of the tail supension test. In the
group of CD-fed Hq animals, the proportion of individuals with a
score of 0 (severely impaired) increased from 5% at 1 month of age
to 80% at 6 months of age (Fig. 9A). The HFD improved tail
suspension test scores in Hq mice suggesting a reduction in the rate
of neurodegeneration: only 42% of animals scored 0 after 6
months (Fig. 9B). Similarly, the percentage of individuals with a
score of 1 (intermediate severity) was 20% at 1 month of age in
both groups and 20% at 6 months of age in the CD-fed Hq
animals versus 58% in the HFD-fed Hq group confirming a slower
progression of the disease (Fig. 9A and B). The proportion of
individuals with a score of 2 (absence of abnormality) was about
75% in both groups at 1 month of age and 0% in both groups at 6
months of age (Fig. 9A and B).
Cerebellar atrophy and baldness are less severe in
HFD-fed Hq mice than in CD-fed Hq animals
We next compared the cerebellar weights between the CD- and
HFD-fed animal groups. In WT animals, diet had no impact on
the cerebellum weight which was significantly higher than in the
Hq population (Fig. 10). In comparison, at 6 months of age, the
average weights of the cerebella of HFD-fed Hq animals were
higher than those of CD-fed Hq mice (Fig. 10). This difference
became statistically significant after correction with the body
weight (Fig. 10; inset).
Finally, baldness has been shown to be a relevant parameter of
disease progression [10]. By scoring baldness in two stages (mild
baldness: ,66% of body surface or severe baldness: .66% of
body surface), we noticed that on average at 6 months of age, the
relative proportion of animals with severe baldness was 60% in the
CD-fed Hq animals and 38% in the HFD-fed Hq animals.
Discussion
This study was initiated to determine our ability to evaluate
therapeutic options in mice in the context of mt disease with
Figure 3. Respiratory chain activities in patient 1 (P1) cells
grown in the absence or presence of palmitate. Cytochrome
oxidase, estimated by the oxidation rate of reduced cytochrome c
(downward deflexion), was about 20% increased in P1 cells cultured
with palmitate (comparison traces a and b). Adding cyanide (KCN) fully
inhibited the oxidation of cytochrome c. The subsequent addition of
succinate (succ), in the presence of rotenone (rot) and additional
oxidized cytochrome c, triggered a cytochrome c reduction (upward
deflexion) which was essentially sensitive to malonate. This succinate-
cytochrome c reductase activity, measuring complex II+III activity, was
about 25% higher in P1 cells grown in the presence of palmitate (b).
Adding glycerol 3-phosphate (G3P) triggered a new increase of
cytochrome c reduction, corresponding to the activity of the glycerol
3-phosphate cytochrome c reductase (glycerol 3-phosphate dehydro-
genase+complex III), 40% higher in cells grown with palmitate (b). The
subsequent addition of decylubiquinol (DQH2) in the presence of EDTA
triggered a rapid cytochrome c reduction which was 90% sensitive to
antimycin (Aa). This antimycin-sensitive quinol-cytochrome c reduction
(complex III activity) did not differ between cells grown in the absence
or presence of palmitate. Numbers along the traces are nmol/min/mg
protein. Values are means 6 SEM from triplicate experiments.
Experimental procedures as described under Materials and methods.
doi:10.1371/journal.pone.0028823.g003
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progression and severity. Because of the well-established ability
of fats to induce mitochondrial biogenesis, we decided to test the
effect of HFD which is often recommended to RC (especially CI)
deficient patients [25,26,27,28]. We first showed that supplement-
ing cell medium with palmitate resulted in protection from cell
death caused by glucose withdrawal in three CI-deficient human
fibroblasts cell lines. This effect was presumably based on the FA-
induced stimulation of mt biogenesis [21,22,23,24], since a
number of mt activities were found increased in our CI-deficient
Figure 4. Box-and-whisker plot of rotarod scores as a function of diet (HFD versus CD) according to age in Harlequin (Hq) and wild
type (WT) animals. The results of three tests per animals performed monthly from one to six months of age are shown with the number (n) of
animals indicated in each box. The vertical bars represent the range of values from the 10
th to the 90
th percentile; the boxes represent the values from
the 25
th to the 75
th percentile; the horizontal lines represent the median value for each group of animals. Isolated circles represent all observations (in
triplicates) below the 10
th percentile or above the 90
th percentile. *: p,0.05; **: p,0.01 (Student’s two-tailed t test). HFD-fed WT mice exhibit
significantly worse performances than the WT mice fed the CD, from 5 months of age due to their obese phenotype (A). From 4 months of age, HFD-
fed Hq mice do significantly better than the Hq fed the CD with a significantly lower progression of the rotarod scores loss (B).
doi:10.1371/journal.pone.0028823.g004
Figure 5. Percentage of individual loss or gain on the rotarod at 6 months of age relative to 1 month of age in Harlequin mice on
control (A) or high fat diet (B). Note the presence of a subset of 6 HFD-Harlequin-responder individuals (dark grey).
doi:10.1371/journal.pone.0028823.g005
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phosphorylation that could have contributed to protect cells from
death both by increasing electron flow in the RC and decreasing
superoxide production [34]. Besides, unlike pyruvate [31],
palmitate did not improve cell ability to handle hydrogen peroxide
insult.
Our study in the Hq mice established that HFD significantly
slowed down disease progression regarding major neurodegener-
ative symptoms (indirectly assessed by rotarod and tail supension
tests [35,36]) and cerebellar atrophy (assessed by cerebellum
weight). While this beneficial effect was observed on average in the
HFD-fed Hq population, it was even more pronounced in a subset
of Hq individuals. This subset population (29%) of responder
animals had a preserved or slightly reduced (#10% of the initial
value) score on the rotarod at 6 months while 100% of CD-fed
animals had a reduced score at a similar time point. The existence
of highly responsive individuals echoes the Hq disease variability
[37]. While we still attempt to understand what could confer diet-
sensibility to a subset of animals, this suggests that individual
therapeutic response is a key-feature of mt disease as reported
recently in Leber Hereditary Optic Neuropathy [38].
Figure 6. Harlequin mice are spared from the weight gain
associated with chronic high fat feeding. Open symbols: wild type
animals; dark symbols: Harlequin mice; squares: CD; circles: HFD. *:
p,0.05; **: p,0.01 (Student’s two-tailed t test). Harlequin mice fed the
CD (n=17 to 20); Harlequin mice fed the HFD (n=21); WT mice fed the
CD (n=21); WT mice fed the HFD (n=21).
doi:10.1371/journal.pone.0028823.g006
Figure 7. HFD-fed individuals exhibit a higher blood level of b-
hydroxybutyrate than the CD-fed individuals. Blood level of b-
hydroxybutyrate (b-OH-butyrate) was determined at 6 months of age,
after 24 hours of fasting in 5 CD-fed WT mice, 5 HFD-fed WT mice, 10
CD-fed Hq mice and 10 HFD-fed Hq mice. **: p,0.01 (Student’s two-
tailed t test).
doi:10.1371/journal.pone.0028823.g007
Figure 8. Box-and-whisker plot of different classes of phos-
pholipids in cerebellum membranes. The abundance of various
phospholipids is expressed in arbitrary units (A.U.) related to their
internal standard and to the cerebellum dry weight (PC, phosphatidyl-
choline; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PS,
phosphatidylserine; SM, sphingomyeline) in 7 WT and 7 Hq individuals.
When compared to CD, HFD-fed individuals exhibit significantly higher
levels of all the phospholipids in cerebellum except from PC in Hq and
SM in WT which are not different between the 2 groups (CD and HFD).
The vertical bars represent the range of values from the 10
th to the 90
th
percentile; the boxes represent the values from the 25
th to the 75
th
percentile; the horizontal lines represent the median value. Isolated
circles represent all observations below the 10
th percentile or above the
90
th percentile. *: p,0.05.
doi:10.1371/journal.pone.0028823.g008
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does not directly participate to energy metabolism [39]. However,
CNS-FAO especially in cerebellum [40] could be involved in the
metabolism of complex cellular lipids that are vital to neuronal
function. This newly described role for FAO in the cerebellum
might play a role in the positive effects of HFD in Hq mice.
Recently, the effects of a massively fat-enriched (ketogenic) diet
were studied on a mouse model with late-onset progressive mt
myopathy [41]; in keeping with our results, these HFD-fed mice
exhibited a slower histological disease progression characterized by
a decreased amount of cytochrome c oxidase negative muscle
fibers.
Altogether, our data not only answer our initial questioning on
the use of Harlequin mice to investigate therapy, but also pave the
way to a number of future researches aiming at 1) qualitatively
improving the HFD for instance by modifying its composition; 2)
testing more non-invasive tools to better appreciate the efficacy of
therapeutic approaches; 3) studying molecular/biochemical/
histochemical biomarkers, that, we and others previously found
affected during the Hq mouse disease and possibly responsive to
HFD.
Finally, we demonstrated that an enriched-fat diet significantly
slowed down disease progression in Harlequin mice, thus
providing additional solid bases for further clinical evaluation of
the HFD in OXPHOS-deficient patients. In contrast to current
dogma, moderate numbers of patients with identical disease (20
per group) should be sufficient to obtain statistically robust
therapeutic indices in the patient population as far as the potential
existence of responders and non responders is recognized. These
findings provide a defined reference which will facilitate preclinical
and early clinical studies targeting mitochondrial disease.
Materials and Methods
Cell culture and cell survival
CI-deficient human fibroblasts previously shown to harbor
mutations in the NDUFS1 gene (2 patients, P1 and P2) [29] and
the NDUFS4 gene (1 patient, P3) [30] were analyzed. Fibroblasts
taken with written informed consent from healthy controls and
patients were grown under standard conditions in Dulbecco
modified Eagle’s medium (DMEM; Gibco Invitrogen, Villebon sur
Figure 9. Tail supension test in Harlequin mice fed the control (A) or high fat (B) diet. From 5 months of age, the proportion of less
severely affected animals is higher in the HFD group (B). The number (n) of animals is indicated in each bar.
doi:10.1371/journal.pone.0028823.g009
Figure 10. Weight of the dissected cerebella at 6 months of age
in wild type (open bars) and Harlequin (dark bars) individuals
fed the control or high fat diet. The number of animals is indicated
inside each bar. The higher weight of cerebella from HFD-fed Hq
animals (compared to CD-fed Hq animals) became significant when
ratios of the cerebellar weight (Cbw) to the animal body weight
(Bw)61000 were compared (inset). ns: non-significant.
doi:10.1371/journal.pone.0028823.g010
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bovine serum, 100 mg/mL penicillin/streptomycin and 4 mM
glutamine in T75 flasks until 100% of confluence and then
transferred to 6-well plates at an initial density of 15,000 cells/cm
2.
24 hours later, after counting, wells were washed with phosphate-
buffered saline (PBS) and cells cultured in 3 different media: 1)
DMEM, 4 mM glutamine; 2) DMEM, 4 mM glutamine, 100 mM
palmitate (Sigma-Aldrich, St Quentin Fallavier, France) and 3)
DMEM, 4 mM glutamine, 2 mM pyruvate (Sigma-Aldrich, St
Quentin Fallavier, France).
In order to allow palmitate entry through plasma cell
membrane, it had to be solubilized with fatty-acid free bovine
serum albumin (BSA, Sigma-Aldrich, St Quentin Fallavier,
France). Stock solutions of palmitate 500 mM/BSA 2.5 mg/mL
were prepared as described elsewhere [42]. Palmitate was
extemporaneously mixed to culture medium with 1 mM L-
carnitine (Sigma-Aldrich, St Quentin Fallavier, France) and
20 mM Hepes (Gibco Invitrogen, Villebon sur Yvette, France)
to obtain a 100 mM final palmitate solution.
Cell survival was assessed every 24 hours as follows. Cells were
trypsinized and collected. The cells were then incubated with an
equal volume of trypan blue and counted using an automated cell
counter (Countess, Invitrogen, Villebon sur Yvette, France). The
experiments were performed in triplicates.
Evaluation of cell survival after H2O2 incubation
Experiments were performed in triplicates in control fibroblasts
which were seeded in 6-well plates at 10,000 cells/cm
2 in 9 different
conditions: 1) DMEM, 4.5 g/L glucose, 4 mM glutamine; 2)
DMEM, 4.5 g/L glucose, 4 mM glutamine, 100 mM palmitate; 3)
DMEM, 4.5 g/L glucose, 4 mM glutamine, 2 mM pyruvate; 4)
DMEM, 4.5 g/L glucose, 4 mM glutamine, 0.001 mg/mL glucose
oxidase (Sigma-Aldrich, St Quentin Fallavier, France); 5) DMEM,
4.5 g/L glucose, 4 mM glutamine, 0.001 mg/mL glucose oxidase,
100 mM palmitate; 6) DMEM, 4.5 g/L glucose, 4 mM glutamine,
0.001 mg/mL glucose oxidase, 2 mM pyruvate; 7) DMEM, 4.5 g/
L glucose, 4 mM glutamine, 0.001 mg/mL glucose oxidase,
350 ng/mL catalase (Sigma-Aldrich, St Quentin Fallavier, France);
8) DMEM, 4.5 g/L glucose, 4 mM glutamine, 0.001 mg/mL
glucose oxidase, 350 ng/mL catalase, 100 mM palmitate; 9)
DMEM, 4.5 g/L glucose, 4 mM glutamine, 0.001 mg/mL glucose
oxidase, 350 ng/mL catalase, 2 mM pyruvate. Cells were counted
24 hours later.
Enzyme assays
Fibroblasts were cultured under 2 conditions (DMEM 4 mM
glutamine; DMEM 4 mM glutamine, 100 mM palmitate) during
48 hours. Then, the cells were trypsinized and centrifuged
5 min61500 g. The supernatant was discarded and the pellet
washed (5 min61500 g) with 1 mL PBS. The majority of the fresh
pellet was used for polarographic assay [43]. A small aliquot of the
pellet was deep-frozen in 20–40 mL PBS solution and subsequently
thawed using 1 mL of ice-cold solution consisting of 0.25 M
sucrose, 20 mM Tris (pH 7.2), 2 mM EGTA, 40 mM KCl and
1 mg/mL BSA, 0.004% digitonin (w/v), and 10% Percoll (v/v)
(medium A). After 7 min incubation at ice temperature, cells were
centrifuged (5 min62300 g), the supernatant discarded, and the
pellet washed (5 min62300 g) with 1 mL of medium A devoid of
digitonin and Percoll. The final pellet was re-suspended in 20–
30 mL of this medium and used for spectrophotometrical enzyme
assays.
Respiratory chain enzyme activities were spectrophotometrical-
ly measured using a Cary 50 UV–visible spectrophotometer
(Varian Inc, Les Ulis, France) [43,44].
Intact cell respiration and mt substrate oxidation (using 0.004%
digitonin-permeabilized cells) were polarographically estimated in
a magnetically-stirred 250 mL-cell thermostated at 37uC (DW1
Clark oxygen electrode; Hansatech Instruments; Norfolk, En-
gland). All chemicals were of the purest grade available from
Sigma-Aldrich (St Quentin Fallavier, France). Protein concentra-
tion was measured according to Bradford.
Animals
Hemizygous (Hq/Y) males were obtained by mating Hq/X
females with wild type (WT) males obtained from the Jackson
Laboratory (Bar Harbor, ME). All mice used in this study were F1
mice bred from founders having a mixed genetic background
(B6CBACaAw-J/A-Pdc8Hq/J). The mice were housed with a 12-
h light/dark cycle with free access to food and water.
From weaning (1 month of age), each animal was alternatively
assigned to one of the 4 groups: Hq fed the control diet (Hq-CD,
n=20),HqfedtheHFDdiet(Hq-HFD,n=21),WTfedthecontrol
diet (WT-CD, n=21) and WT fed the HFD (WT-HFD, n=21).
Ethics Statement
The ethics committee of Robert Debre ´ University Hospital
(APHP, 75019 Paris, France) approved the study on human
fibroblasts. Informed written consent was obtained from healthy
controls, probands (if possible) and parents.
Details of the mouse study were submitted to and approved by the
Debre ´-Bichat Ethics Committee on Animal Experimentation
(http://www.bichat.inserm.fr/comite_ethique.htm) - Protocol Num-
ber 2010-13/676-0003 - (in accordance with the French law on
animal protection).
Genotype determination
Mice were genotyped using multiplex PCR as already reported
[10].
Phenotypic evaluation
Growth retardation, baldness and cerebellar ataxia have already
been studied as relevant markers of disease progression [10] and
were monthly studied between one and six months of age.
Cerebellar ataxia was assessed using two indirect tests. 1) The
rotarod test specifically evaluates coordination and balance [32].
Mice walked on a computer-driven rotating rod (Imetronic;
Pessac, France) at speeds that increased from 4 to 40 rpm at 1, 2,
3, 4, 5, and 6 months of age, for 4 consecutive days after training
the day before. The time of falling from the rod was recorded. The
3 better of 4 consecutive attempts were kept and the arithmetic
mean of these 3 values set aside for further analysis. 2) The tail
supension test is a marker of disease progression in a number of
mouse models of neurodegeneration [35], including the large
group of cerebellar ataxias [36]. Mice were scored as followed:
After grasping the tail near its base and lifting the mouse clear of
all surrounding objects, the hindlimb position was observed for 10
seconds. If the hindlimbs were consistently splayed outward, away
from the abdomen, it was assigned a score of 2, as in WT mouse. If
one or both hindlimbs were retracted toward the abdomen for
more than 50% of the time suspended, it received a score of 1. If
its hindlimbs were entirely retracted and touching the abdomen
for more than 50% of the time suspended, it received a score of 0
(the most severe phenotype).
Diet protocol
HFD was a fat-enriched modification of the CD (R04, SAFE
diets, Augis, France). HFD consisted of fat 30 kcal%, carbohydrate
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carbohydrate 72 kcal% and protein 20 kcal%. Both diets were
designed to be isocaloric with approximately 3000 kcal/kg of
chow. CD contained 77% of unsaturated fatty acids (of which 75%
were polyunsaturated fatty acids, PUFA) and 23% of saturated
fatty acids. HFD contained 54% of saturated fatty acids and 46%
of unsaturated (of which 33% were PUFA). Daily chow
consumption was measured for 3 consecutive days in four 3-
month aged mice of each group.
b-hydroxybutyrate determination and phospholipid
profiling of cerebellum membranes
At 6 months of age, after 24 hours of fasting, the mice were
sacrificed by cervical dislocation and cerebellum was dissected and
weighted. Blood b-hydroxybutyrate was determined with Optium
Xceed (MediSense, ABOTT, Rungis, France).
Phospholipid profiling of cerebellum membranes was performed
in 14 Hq individuals (7 HFD-fed and 7 CD-fed) and in 14 WT
individuals (7 HFD-fed and 7 CD-fed) as already reported [45].
Cerebella were ground in 1600 mL of 0.1 N HCl and then extracted
with 1600 mL of methanol containing internal standards (1.5 mM
1,2-dinonadecanoyl-sn-glycero-3-phosphocholine; 0.25 mM 1,2-
sn-diphytanoyl-glycero-3-phosphoethanolamine; 0.25 mM N-hep-
tadecanoyl-D-erythro-sphingosylphosphorylcholine) and 1600 mL
of chloroform. After intense stirring for 10 minutes and 1 hour of
settling, the solution was centrifuged at 6000 g for 5 minutes. The
lower organic phase was extracted and evaporated to dryness under
nitrogen gas stream. The dry residue was taken up in 100 mLo f
chloroform and diluted with 900 mL methanol. 100 mLo ft h i s
solution were then injected into a liquid chromatography coupled to
tandem mass spectrometry (LC/MS-MS) analyzer to quantify
various phospholipids classes (PC, phosphatidylcholine; PE, phso-
phatidylethanolamine; PI, phosphatidylinositol; PS, phosphatidyl-
serine; SM, sphingomyeline).
Statistics
We used a two-factor, repeated-measures ANOVA (STAT-
VIEW 5.0, SAS Institute, Cary, NC) to test for significant main
effects and interactions between main effects. Where ANOVA was
significant, t tests were applied a priori. P#0.05 was considered
significant. Values are means 6SEM.
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